Ensitrelvir for the Treatment of Nonhospitalized Adults with COVID-19: Results from the SCORPIO-HR, Phase 3, Randomized, Double-blind, Placebo-Controlled Trial.
Saved in:
| Title: | Ensitrelvir for the Treatment of Nonhospitalized Adults with COVID-19: Results from the SCORPIO-HR, Phase 3, Randomized, Double-blind, Placebo-Controlled Trial. |
|---|---|
| Authors: | Luetkemeyer AF; Division of HIV, Infectious Diseases and Global Medicine, Zuckerberg San Francisco General, University of California San Francisco, San Francisco, California, USA., Chew KW; Division of Infectious Diseases, Department of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California, USA., Lacey S; Biostatistics, Shionogi B.V., London, United Kingdom., Hughes MD; Center for Biostatistics in AIDS Research, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA., Harrison LJ; Center for Biostatistics in AIDS Research, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA., Daar ES; Division of HIV Medicine, Lundquist Institute at Harbor University of California Los Angeles, Torrance, California, USA., Eron J; Division of Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA., Fletcher CV; UNMC Center for Drug Discovery, University of Nebraska Medical Center, Omaha, Nebraska, USA., Greninger AL; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA., Hessinger D; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA., Li JZ; Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA., Mailhot D; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA., Wohl D; Division of Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA., Chayakulkeeree M; Division of Infectious Diseases and Tropical Medicine, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand., Mendoza JLA; Internal Medicine Department, IPS Centro Cientifico Asistencial S.A.S., Barranquilla, Colombia., Elistratova P; Clinical Development, Shionogi Inc., Florham Park, New Jersey, USA., Makinde O; Clinical Development, Shionogi Inc., Florham Park, New Jersey, USA., Morgan G; Portfolio Management, Shionogi Inc., Florham Park, New Jersey, USA., Portsmouth S; Clinical Development, Shionogi Inc., Florham Park, New Jersey, USA., Uehara T; Drug Development and Regulatory Science Division, Shionogi & Co., Ltd., Osaka, Japan., Smith D; Antiviral Research Center, University of California, San Diego, California, USA., Currier JS; Division of Infectious Diseases, Department of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California, USA. |
| Source: | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2025 Jul 18; Vol. 80 (6), pp. 1235-1244. |
| Publication Type: | Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Oxford University Press Country of Publication: United States NLM ID: 9203213 Publication Model: Print Cited Medium: Internet ISSN: 1537-6591 (Electronic) Linking ISSN: 10584838 NLM ISO Abbreviation: Clin Infect Dis Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1537-6591 |
|---|---|
| DOI: | 10.1093/cid/ciaf029 |
